On September 11, Boston Scientific fell 3.13% in regular trading, trading at $43.555 per share, with turnover of approximately $492 million. The decline reflects the ongoing impact of a cybersecurity incident compounded by a price target cut and persistent margin headwinds.

Citigroup lowered its price target on Boston Scientific to $57 from $61 while maintaining a Buy rating. The average analyst target stands at $61.11 according to FactSet. The company had previously disclosed via SEC filings that a cybersecurity incident first identified on August 25 caused network outages affecting IT systems, disrupting global operations including customer order processing and product shipment. Boston Scientific explicitly warned it is unlikely to meet its Q3 and full-year net sales growth and adjusted EPS guidance ranges.

Executives noted the company faces gross margin pressure tied to its Watchman product line and electrophysiology trends, while simultaneously pushing forward a significant restructuring plan expected to yield financial benefits. Management is reassessing its 2027 strategic framework in light of the cyber event, with updated forward guidance expected at the October earnings call. Truist Securities indicated that both near-term and 2027 estimates will likely need to come down, though the risk/reward profile remains tilted to the upside over the next six to twelve months.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)